DC
KYMR icon

Diametric Capital’s Kymera Therapeutics KYMR Stock Holding History

Diametric Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,600
Closed -$288K – 443
2025
Q2 		$288K Buy
+6,600
New +$227K 0.15% 187

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Diametric Capital's KYMR Position: Q3 2025 in Review

Diametric Capital sold out of Kymera Therapeutics (KYMR) in Q3 2025, closing a stake of 6,600 shares — an estimated $288K sold.

Diametric Capital first reported a position in KYMR in Q2 2025 and held it in 1 quarter. The position peaked at $288K in Q2 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q3 2025.

  • Diametric Capital reported no remaining Kymera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Diametric Capital sold 6,600 Kymera Therapeutics shares in Q3 2025, an estimated $288K.
  • Diametric Capital first reported a position in Kymera Therapeutics in Q2 2025 and held it in 1 quarter.
  • Diametric Capital's Kymera Therapeutics position peaked at $288K in Q2 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2025.

Based on Diametric Capital's 13F filing for Q3 2025, filed 13 Nov 2025.